ICON plc (NASDAQ:ICLR) today announced that it has selected Microsoft as a preferred technology partner – further advancing ICON’s previously announced plan to invest in digital innovation and AI over the next three years. This partnership incorporates an enterprise-wide deployment of Microsoft 365 Copilot along with an enterprise-grade cloud, data and AI infrastructure to further scale Orbis, ICON’s secure, governed agentic AI platform.

Through Orbis, ICON is building an intelligence layer that connects expertise, data, and AI across the trial lifecycle. By combining frontier model capabilities with ICON's operational expertise, it has significant impacts on the trial lifecycle through:

  • Accelerating study design using AI‑enabled protocol digitisation, optimisation and scenario modelling.
  • Streamlining operational execution, supporting workflows across feasibility, site identification, start‑up, monitoring, data review and regulatory documentation.
  • Enhancing patient and site engagement, offering intelligent assistants for burden reduction, safety insights and improved communication.
  • Strengthening decision‑making, enabling real‑time detection of risks, trends and operational signals.

The partnership with Microsoft directly supports the three key focus areas of ICON’s AI strategy:

  1. Intelligence Layer. Microsoft will support the development of a modern data layer, powered by Microsoft Fabric and Azure data services, that connects, harmonises and governs ICON’s clinical, operational and enterprise data. This unified foundation gives Orbis trusted, real-time data at scale enabling better decisions, faster.
  2. Productivity. ICON is expanding Microsoft 365 Copilot and Copilot Chat to every employee across the organisation – enabling the automation of high-volume, repeatable tasks and redirecting human expertise to higher-value activities.
  3. Domain-specific agents. Using Microsoft Azure, Microsoft AI Services and Microsoft Foundry – alongside access to other frontier models – ICON will further develop and deploy agents embedded directly within clinical trial workflows, securely and responsibly, accelerating the path from prototype to production-grade agentic AI.